• All sections
  • C - Chemistrymetallurgy
  • C07D - Heterocyclic compounds
  • C07D 241/12 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Patent holdings for IPC class C07D 241/12

Total number of patents in this class: 485

10-year publication summary

46
47
34
53
39
42
36
39
24
15
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

Principal owners for this class

Owner
All patents
This class
Semiconductor Energy Laboratory Co., Ltd.
11398
13
Bristol-myers Squibb Company
4878
10
Amgen Inc.
4072
10
Guangzhou Magpie Pharmaceuticals Co., Ltd.
29
10
Abbvie Inc.
1802
8
Merck Sharp & Dohme LLC
3750
8
Calico Life Sciences LLC
96
7
F. Hoffmann-La Roche AG
7930
6
Hoffmann-La Roche Inc.
3414
6
Massachusetts Institute of Technology
10051
6
The General Hospital Corporation
4726
6
Arcus Biosciences, Inc.
138
6
The Broad Institute, Inc.
1805
6
Nippon Soda Co., Ltd.
894
6
Novartis AG
10847
5
The Regents of the University of California
19898
5
Syngenta Crop Protection AG
6045
5
Bayer Pharma AG
1053
5
Novaled GmbH
441
5
Vivace Therapeutics, Inc.
30
5
Other owners 347